Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Source filing unavailable
Q2 2014 · —
Revenue$204.06M$204.06M+36.8% vs Q2 2013 Net Income$50.36M$50.36M+43.7% vs Q2 2013 EPS Diluted$0.66$0.66+57.1% vs Q2 2013 Operating Income$82,999,000+49.3% Operating Cash Flowderived$47,549,000+115.0% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Free Cash Flowderived
Margins · derivedOperating margin40.7%+3.4 pt vs Q2 2013
Net margin24.7%+1.2 pt vs Q2 2013